Sera Prognostics PRIME study meets both co-primary endpoints; cash $68.2M

SERA PROGNOSTICS, INC.

Cash, cash equivalents, and marketable securities were approximately $68.2 million as of December 31, 2024 (preliminary).
PRIME study met both co-primary endpoints: 25% reduction in neonatal morbidity (NMI) and 18% reduction in neonatal length of stay in mITT population.
ITT analysis: 20% reduction in NMI, 8% reduction in neonatal stay, and 20% reduction in NICU admissions.
PreTRM test classified 23.5% as higher risk; number needed to screen 3-4 to save one NICU day.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.